Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (https://pubmed.ncbi.nlm.nih.gov/35603936/). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations.

 

 

Download entire guideline document in the latest version (September 2023, partial update February 2025): 

Download
9434

Last updated
Changes
Download
Introduction, scoping, population and targeted users
09/2023
Editorial changes
Download
616
Disease severity and treatment goals
09/2023
No changes
Download
1128
Methods and evidence section
02/2025
Editorial changes
Download
303
Main Recommendations and Decision Grid
02/2025
Pregnancy changes were added
Download
1559
Implementation slides
02/2025
New data added
Download
579
IFPA Guideline
09/2023
Editorial changes
Download
594

Last updated
Changes
Download
Acitretin
03/2023
No changes, minor editorial changes in 2025
Download
473
Ciclosporin
03/2023
Reference added
Download
407
Fumarates
03/2023
No changes
Download
183
Methotrexate
03/2023
New data added, pregnancy changes were added in 2025
Download
696
Adalimumab
03/2023
No changes, minor editorial changes in 2025
Download
334
Apremilast
03/2023
New data added
Download
391
Bimekizumab
09/2023
New data added
Download
292
Brodalumab
09/2023
New data added
Download
128
Certolizumab – Pegol
09/2023
No changes, minor editorial changes in 2025
Download
140
Deucravacitinib
02/2025
Recommendation concerning laboratory controls updated
Download
317
Etanercept
03/2023
No changes
Download
97
Guselkumab
03/2023
No changes
Download
270
Infliximab
03/2023
No changes, minor editorial changes in 2025
Download
127
Ixekizumab
09/2023
New data added
Download
206
Risankizumab
09/2023
New data added
Download
350
Secukinumab
09/2023
New data added
Download
222
Tildrakizumab
03/2023
No changes
Download
168
Ustekinumab
03/2023
No changes
Download
169
Biosimilars
09/2023
New data added, minor changes in 2025
Download
139
Newly approved medications and treatments in the pipeline
10/2021
No changes
Download
288

Last updated
Changes
Download
Psoriatic arthritis
03/2023
New data added, recommendations changed
Download
507
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Download
208
Cancer
09/2023
New data added, minor changes in 2025
Download
579
Depression
09/2023
New data added, minor editorial changes in 2025
Download
152
Diabetes Mellitus
09/2023
New data added, recommendations changed, minor changes in 2025
Download
227
Heart disease
03/2023
New data added, minor editorial changes in 2025
Download
277
Kidney disease
03/2023
New data added
Download
142
Neurological diseases
09/2023
New data added, minor editorial changes in 2025
Download
171
Viral Hepatitis
02/2025
New data added, recommendations changed
Download
227
Tuberculosis: Screening
09/2023
Editorial changes, minor editorial changes in 2025
Download
241
Tuberculosis: Treatment
09/2023
Editorial changes, minor editorial changes in 2025
Download
249
Wish for child / Pregnancy
02/2025
New data added, recommendations changed
Download
441
Vaccinations
03/2023
Completely new written
Download
304
Inmunogenicity
10/2021
No changes
Download
124

Last updated
Changes
Download
Methods Report
02/2025
Editorial changes
Download
243
Strength and limitations
09/2023
No changes
Download
82
Abbreviations
09/2023
Editorial changes
Download
39